These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index. Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292 [TBL] [Abstract][Full Text] [Related]
4. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372 [TBL] [Abstract][Full Text] [Related]
5. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and survival in malignant pleural mesothelioma. Van Gelder T; Damhuis RA; Hoogsteden HC Eur Respir J; 1994 Jun; 7(6):1035-8. PubMed ID: 7925870 [TBL] [Abstract][Full Text] [Related]
7. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma. Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S Tumori; 2016; 102(2):190-5. PubMed ID: 26893272 [TBL] [Abstract][Full Text] [Related]
8. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812 [TBL] [Abstract][Full Text] [Related]
9. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Nojiri S; Gemba K; Aoe K; Kato K; Yamaguchi T; Sato T; Kubota K; Kishimoto T Jpn J Clin Oncol; 2011 Jan; 41(1):32-9. PubMed ID: 20798232 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. Ak G; Metintas S; Metintas M; Yildirim H; Erginel S; Kurt E; Alatas F; Cadirci O J Thorac Oncol; 2009 Nov; 4(11):1425-30. PubMed ID: 19752758 [TBL] [Abstract][Full Text] [Related]
11. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651 [TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622 [TBL] [Abstract][Full Text] [Related]